Navigation Links
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
Date:2/11/2009

mcy, M.D., president and chief executive officer of Portola. "By combining their strengths with our own research and development expertise in thrombosis, we have a great opportunity to significantly improve the lives of millions of patients worldwide."

Elinogrel is the only direct acting, reversible, i.v. and oral P2Y12 ADP receptor antagonist in clinical development. Inhibiting the P2Y12 ADP receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Because of its properties, elinogrel has the potential to provide significant clinical advantages compared to Plavix(R)* (clopidogrel), the current standard of care, and to newer agents in development, such as prasugrel, by lowering the risk of ischemic events due to clot formation and reducing the risk of bleeding. In addition, elinogrel is the only compound in development that can be administered intravenously in the hospital and orally in the chronic setting.

In Portola's clinical studies to date with the i.v. and oral formulations, results showed that elinogrel appeared to be well-tolerated without serious adverse events and demonstrated predictable, dose-dependent platelet inhibition. At the American Heart Association Scientific Sessions in November 2008, Dr. Paul Gurbel presented data that showed elinogrel overcomes high platelet reactivity, which is a known marker for adverse ischemic events in patients non-responsive to clopidogrel.

In December 2008, Portola initiated patient enrollment in INNOVATE-PCI, an 800-patient Phase 2 clinical trial of the i.v. and oral forms of elinogrel in a broad group of patients undergoing non-urgent percutaneous coronary intervention. Portola, together with Novartis, plans to further develop elinogrel to treat patients with acute coronary syndromes and broadly in patients with a prior heart attack or stroke, and those with peripheral vascular disease.

* Plavix(R) is
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... that they monopolize large amounts of sugar. More recently, ... characterized by a series of features such as mobility ... are calling this behavior "mesenchymal," and they suspect it ... was able to demonstrate that the two observations ... the same mechanism, at least in "non-small cell lung ...
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 A lush ... family playtime during the summer. However, the summer heat, lack ... lawn to become brown, weak and unhealthy. The Grounds Guys ... It Grow, Mow a lawn once a week and set ... than normal. This protects the grass roots from heat and ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... 2014 Dawn Echols’ professional background ... and music. This experience has honed her people ... psychology. Her professional counseling ( http://dawningphoenix.com ) work ... for offenders in domestic violence. , As ... she enjoys counseling individuals and groups for a ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... Perot Systems,Corporation (NYSE: PER ) ... received the #1 ranking in the KLAS ... implementation services(1). Known throughout,the Healthcare industry for ... informed technology decisions by independently,monitoring vendor performance ...
... LA JOLLA, CA Diabetic individuals have a ... the molecular connection between the two remains unexplained. ... Studies identified the probable molecular basis for the ... published in the current online issue of Neurobiology ...
... How Drugs Actually Work in Real ... ... free,patient-driven online healthcare community, announced the launch of an,innovative new tool that ... taking prescription drugs, and eight out of,ten surfing the web for their ...
... Hillenbrand, Inc.,(NYSE: HI ) today announced that ... a publicly traded company of $0.1825 per share,on the ... 2008 to,shareholders of record at the close of business ... board to approve this inaugural dividend is based,on the ...
... Pet Week, May,4-10, celebrates the relationships formed between ... emphasize the caretaking actions we can take for ... recommended by,your veterinarian; giving them plenty of attention, ... pets safe and pleasant., "Being a responsible ...
... Tex. April 30, 2008 - Despite the general ... critically ill heart failure patients, implantation of these devices ... high-volume blood transfusions during and immediately after surgery. A ... that the incidence of these complications may be significantly ...
Cached Medicine News:Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 2Health News:Perot Systems Ranked #1 for Clinical Implementation Services By KLAS 3Health News:Salk study links diabetes and Alzheimer's disease 2Health News:Salk study links diabetes and Alzheimer's disease 3Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 2Health News:iGuard.org Alters the Face of E-Health: New Web Service Draws 10,000 New Patients Weekly 3Health News:Hillenbrand, Inc. Declares First Quarterly Dividend As a New Publicly Traded Company 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 2Health News:California Veterinarians Recognize National Pet Week With Tips to Keep Your Animal in a Safe Environment 3
(Date:7/28/2014)... N.J. , July 28, 2014   ... $520,000 settlement of off-label marketing and fraud claims ... and Vascular Solutions, Inc. ("VSI").  The settlement covers ... medical devices for endovenous laser ablation of varicose ... Magnanini, a firm with a history of representing ...
(Date:7/28/2014)... -- June 28 th , 2014 – Oncolab, the ... cancer test, is making its AACC debut (booth #4051) at ... is a serum-based in vitro immunoassay, has been run for ... in the fight against cancer recurrence. Photo - ... million cancer survivors in the US alone, the race is ...
(Date:7/28/2014)... 2014 Reportlinker.com announces that a new ... Portugal Pharmaceuticals and Healthcare Report ... Includes 3 FREE quarterly ... growth last quarter has led us to revise ... forecast previously, BMI expects Portugal,s ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... Prostate Conditions Education Council (PCEC) – a ... in prostate cancer screening – today announced it strongly ... Services Task Force (USPSTF). The draft guidance recommends against ... PCEC believes that until a more accurate and ...
... 10, 2011 PDI, Inc. (Nasdaq: ... R. Melillo, Jr. as senior vice president of Business ... drive PDI,s commercial outsource services and contract sales business. ... officer. Melillo was most recently general manager ...
Cached Medicine Technology:Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 2Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 3PDI Appoints Gerald R. Melillo, Jr. As SVP of Business Development 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... nm and 940 nm) laser system is ... solid-state laser quickly and effectively treats vascular ... offers the clinical versatility to precisely target ... vessels in a convenient, affordable package. , ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: